The numbers are fine. Revenue, operating profit, governance, reporting, board composition — all where they should be. The issue is not the company. The issue is the market it has to exit into. The IPO window that was meant to be available never reopened, and the trade-sale bids are not numbers the investment committee wants to take to LPs.
Every year that passes makes it harder to call this simply a question of timing.
The standard responses are familiar. Extend the fund and buy time without buying certainty. Accept the trade-sale price and close the file. Or route the asset into a continuation vehicle — increasingly the default answer, and for many assets the right one. But a continuation vehicle still requires LPs to evaluate a transaction in which the same manager remains involved on both sides, creating an inherent conflict that must be independently managed. Some LPs are now being asked to consider a second continuation transaction involving the same asset. It solves for liquidity. It does not solve for a public price.
There is a fourth route.
For the right profile — audited, profitable, industrial or medical, already operating at institutional standard — it is possible to treat the company as a candidate for a U.S. public listing, with part of the fund's holding converted into listed stock and part into cash. The price is established with a committed counterparty before anything becomes public. If the number does not work, the process stops there, and nothing has been disclosed. The listing is not pursued as a story; it is pursued as a structure. The point is not to manufacture a better multiple. The point is to create a path to liquidity and greater control over the timing of realisation than a single trade buyer or a same-manager transfer can offer.
The mandate is narrow. The focus is on industrial and medical device companies with established revenue, operating profit, and existing approvals where relevant, in sectors where credible institutional demand can be established before a transaction proceeds: defence and dual-use manufacturing, power and electrical equipment, energy hardware that already ships product, and cleared medical devices with existing customers. It is not a route for early-stage, narrative-led holdings.
What this does not do is turn a weak asset into a strong one. If the company has governance issues, patchy reporting, or uncertain customers, the structure will not fix it. If the asset is in a sector U.S. investors are currently punishing, the listing will not rescue it. The screen is strict on purpose.
What it can do, in the right case, is turn one indivisible holding inside a closed-end fund into a mix of cash and listed stock, with a timetable the fund can manage rather than one dictated entirely by a single buyer or a single co-investor. Where the transaction is supported by committed capital, part of the holding may be realised at closing, while the balance is retained, distributed in kind where the fund documents permit, or sold down over time. The exit is no longer binary between "trade sale now at a number nobody likes" and "extend, transfer, or hope."
For LPs and fund partners weighing a continuation vehicle against a discounted sale, that fourth option changes the conversation. The decisive question is not whether the company deserves another route. It is whether credible institutional capital can be committed before that route is pursued.
Fund partners, portfolio-company chairs, CEOs and CFOs who recognise this pattern are welcome to explore whether a holding fits the profile.